These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 32439455)

  • 1. Long-Term Follow-up of Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Kung FF; Starr MR; Bui YT; Mejia CA; Bakri SJ
    Ophthalmol Retina; 2020 Nov; 4(11):1047-1053. PubMed ID: 32439455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS.
    Starr MR; Kung FF; Mejia CA; Bui YT; Bakri SJ
    Retina; 2020 Sep; 40(9):1665-1672. PubMed ID: 31725524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration: A Prospective Study.
    Maruko I; Ogasawara M; Yamamoto A; Itagaki K; Hasegawa T; Arakawa H; Nakayama M; Koizumi H; Okada AA; Sekiryu T; Iida T
    Ophthalmol Retina; 2020 Aug; 4(8):767-776. PubMed ID: 32417356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
    Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J
    Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
    Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
    Peden MC; Suñer IJ; Hammer ME; Grizzard WS
    Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
    Lee SJ; Koh HJ
    Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.
    Vardarinos A; Gupta N; Janjua R; Iron A; Empeslidis T; Tsaousis KT
    BMC Ophthalmol; 2017 Apr; 17(1):58. PubMed ID: 28449645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gas-mediated vitreomacular adhesion release with intravitral ranibizumab injections for exudative age-related macular degeneration.
    Kang HM; Lee SJ; Kim CG; Chung EJ; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1681-92. PubMed ID: 26743753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
    Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
    Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
    Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis.
    Christenbury JG; Phasukkijwatana N; Gilani F; Freund KB; Sadda S; Sarraf D
    Retina; 2018 Jul; 38(7):1276-1288. PubMed ID: 28723848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study: Report 1: Ten-Year, Real-World Outcomes.
    Spooner K; Fraser-Bell S; Hong T; Phan L; Wong JG; Chang A
    Ophthalmol Retina; 2021 Jun; 5(6):511-518. PubMed ID: 33007523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Factors and Long-term Surgical Outcomes for Exudative Age-related Macular Degeneration with Breakthrough Vitreous Hemorrhage.
    Kim TY; Kang HG; Choi EY; Koh HJ; Kim SS; Lee JH; Kim M; Byeon SH; Lee CS
    Korean J Ophthalmol; 2020 Aug; 34(4):281-289. PubMed ID: 32783420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Evolution of Fibrosis and Atrophy and Their Relationship with Visual Outcomes in Asian Persons with Neovascular Age-Related Macular Degeneration.
    Cheung CMG; Grewal DS; Teo KYC; Gan A; Mohla A; Chakravarthy U; Wong TY; Jaffe GJ
    Ophthalmol Retina; 2019 Dec; 3(12):1045-1055. PubMed ID: 31444144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19.
    Keenan TD; Vitale S; Agrón E; Domalpally A; Antoszyk AN; Elman MJ; Clemons TE; Chew EY;
    Ophthalmol Retina; 2020 Jan; 4(1):3-12. PubMed ID: 31395505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes.
    Ciulla TA; Hussain RM; Pollack JS; Williams DF
    Ophthalmol Retina; 2020 Jan; 4(1):19-30. PubMed ID: 31324588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
    Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.